CARA - Cara Therapeutics, Inc.
| Previous Close | 17.05 |
| Open | 17.06 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 1000 |
| Day's Range | 16.86 - 17.36 |
| 52 Week Range | 11.46 - 24.30 |
| Volume | 528,576 |
| Avg. Volume | 610,029 |
| Market Cap | 666.651M |
| Beta (3Y Monthly) | 3.17 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.98 |
| Earnings Date | Aug 3, 2017 - Aug 7, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 25.30 |
- GlobeNewswire•5 days ago
Consolidated Research: 2019 Summary Expectations for Tenaris S.A, Rapid7, Halozyme Therapeutics, Cara Therapeutics, EnPro Industries, and K12 — Fundamental Analysis, Key Performance Indications
NEW YORK, Feb. 15, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- InvestorPlace•7 days ago
Should You Buy, Sell, Or Hold These 7 Medical Cannabis Stocks?
Cannabis stocks are having a blistering start to 2019. The sector appeared to have peaked in the fall of 2018. As many had warned, marijuana stocks turned sharply lower following Canada's legalization going into effect in a classic "sell the news" event. However, since then, the tide has turned. This year, pot stocks are back with the sector ETF posting a 50% move off the lows. * 9 U.S. Stocks That Are Coming to Life Again Not surprisingly, this enthusiasm has carried both recreational and medicinal cannabis stocks higher. For today, let's focus on the medicinal space. The recreational plays have been getting more attention lately with all the blockbuster partnerships. However, there are some interesting business stories developing in the medical cannabis stock space as well.InvestorPlace - Stock Market News, Stock Advice & Trading TipsSource: Shutterstock Aurora Cannabis (ACB)Aurora Cannabis (NYSE:ACB) is getting a ton of attention this week thanks to its recent earnings report. Aurora initially disappointed the market as its revenue numbers came in below expectations. This point raised some confusion. The company reported CAD $48 million in cannabis revenues, which was below expectations. Total revenues, which included a few other minor accounting items, hit CAD $54 million. That number beat analysts' outlooks.ACB stock initially dropped about 5% following earnings. Since then, it reversed course and traded higher. That makes sense; at the end of the day, it's the forward outlook that matters here, not a few million dollars of revenue this past quarter. On that note, the most solid bullish argument for ACB stock is that its patient base is surging. This quarter, it reported more than 73,000 active registered patients -- more than 200% growth from the same quarter last year.Of course, bears will point to the huge losses that Aurora is reporting. The company lost CAD $238 million, which blows the revenue figure of CAD $54 million out of the water. Some of these losses appear tied to ramping up operations. For the back half of the year, Aurora projects positive EBITDA, and much smaller net income losses. That, combined with relatively downbeat sentiment here, make ACB stock a buy within its sector. Do be careful though, Aurora needs to start posting much smaller losses as its customer base increases or investors will lose patience fairly quickly. GW Pharmaceuticals (GWPH)When it comes to medical cannabis stocks -- as opposed to the recreational lane -- GW Pharmaceuticals (NASDAQ:GWPH) is the king. GW Pharmaceuticals got involved with its epilepsy drug well before the flood of marijuana stocks hit the market last year.GW capitalized on its first-mover advantage by already securing FDA approval for its therapy while other cannabis stocks are still getting their operations up and going. The company has gotten widespread insurance coverage approval for its drug, Epidiolex. * The 7 Best Video Game Stocks to Power Up Your Portfolio! Earlier this year GW confirmed that the vast majority of both fee-for-service and managed- Medicaid providers will cover Epidiolex. Big private providers, such as Express Scripts (NASDAQ:ESRX) are on board as well. GW recently raised $300 million. That cash should give it plenty of runway to get Epidolex sales up and going while also funding its numerous other in-progress clinical trials. For a pureplay marijuana biotech stock, it's hard to top GWPH.Source: Shutterstock Cara Therapeutics (CARA)Cara Therapeutics (NASDAQ:CARA) is a bit more undercover as a cannabis stock. The company specializes in various therapeutic treatment alternatives that can serve as alternatives to opioids. As we've seen in recent months, opioids are a crisis in America. An estimated 30,000 people or so die from overdoses every year.This opens an opportunity for Cara, which I previously described. As it is, Cara has various drug therapies in development for pain management. Some of these involve cannabinoids, although its lead clinical candidate does not. In any case, with China increasingly in the news, CARA stock should shine as doctors look for alternatives to dangerous traditional opioids. CARA stock is up from $12 to $17 recently and could rise a lot farther once it picks up more backers from the medical marijuana stock community.Source: Shutterstock KushCo Holdings (KSHB)KushCo Holdings (OTCMKTS:KSHB) is arguably the clearest medical marijuana distribution play in the United States at this time. The company used to be called Kush Bottles, which shows the company's main product line. However, KushCo has branched out past just packaging to provide a variety of supplies for medicinal marijuana sales. By partnering with more than 5,000 pharmacies and dispensaries around the world, KushCo has established a powerful first-mover advantage in its field.That said, there are reasons for caution with KSHB stock. You might think that this is a cheap stock. It is trading for less than $6 and is not listed on a major stock exchange. Despite those factors, KushCo has a market cap of more than $500 million, as the company has issued many shares to fund its growth. * The 3 Best Chinese Stocks to Buy for a Long-Term Portfolio As appealing as the "picks and shovels" play on the marijuana industry sounds, KSHB stock comes with risks. That $500 million market cap is backed by just $50 million or so in current assets, putting a 10x valuation multiple on its property, inventory, cash, and so on. Also, you should take note of the company's gross margin. Its gross margin has plummeted from 35% to 13% in recent quarters, resulting in KushCo making increasingly large losses despite growing revenues. KushCo has an interesting business model and a strong advantage from its robust distribution partnerships. But it needs to start showing that the business can turn profits before the stock can find further upside.Source: Shutterstock Pyxus International (PYX)What happens when a struggling more-than-century old tobacco company turns itself into a marijuana play? The stock soars. Meet the company previously called Alliance One, now known as Pyxus International (NYSE:PYX). For the past two decades or so, Alliance One showed flat to declining revenues as its tobacco business declined. So, last summer, using the hemp workaround to avoid legal issues, Pyxus pivoted to the marijuana market and changed its name, and PYX stock flew.In fact, PYX stock soared from $13 at the start of 2018 to as high as $40, aided by favorable calls from the likes of Citron Research, among others. But the enthusiasm wouldn't last long. Once investors came to their senses, they saw that Pyxus remained heavily in debt and stuck to its legacy tobacco business which faces uncertain prospects going forward. There are a lot of cannabis stocks out there; there aren't many that have more than a billion in debt like Pyxus does.PYX stock soared more than 30% on Tuesday following its earnings report. The market clearly liked what it saw, starting with nearly 10% revenue growth. But the company continues to lose large amounts of money. It reported a GAAP EPS loss of 56 cents per share. It will need a far bigger turnaround to justify anything close to its current share price. The recent share price spike offers speculators an ideal opportunity to sell PYX stock.Source: Shutterstock GB Sciences (GBLX)GB Sciences (OTCMKTS:GBLX) is -- in one way similar -- to KushCo. Despite trading on the Pink Sheets and having a tiny share price, GBLX stock isn't necessarily undervalued. GBLX stock, in fact, sells for under a quarter but, due to a large share count, has a market cap of almost $60 million.I don't want to pick on GBLX stock in particular, as there are a bunch of medical cannabis stocks like GBLX. But it's worth noting one like this to see the pattern. You find a bunch of these, companies that are attached to whatever the current trend is popular but don't have many resources of their own. * Buy Medical Marijuana Stocks for Legal Pot's Next Leg Up In the case of GB Sciences, they had just $3 million in cash as of their last quarterly report. That's not a good sign, as the company has $2.1 million in current liabilities and more than $8 million in total obligations. That will make it hard for the company to achieve its goals in terms of studying Parkinson's and other serious diseases. Yes, GB will put out more press releases and garner more media attention, but without far more cash, the stock isn't going anywhere in the long run. GBLX stock plummeted from a high of 80 cents to just 14 cents last year. If you're already long, take advantage of the recent rebound to get out at 24 cents -- GBLX will likely go a lot lower in coming months.Source: Shutterstock Lexaria Bioscience (LXRP)Lexaria Bioscience (OTCMKTS:LXRP), like GB Science, is a penny stock on the Pink Sheets exchange. However, LXRP has a lot more credibility and gives us a good example of the contrast between an investable speculation and a risky gamble. Lexaria is a higher-quality medical cannabis stock because it has a strong backer: Altria (NYSE:MO).Altria famously lifted Cronos (NASDAQ:CRON) into the big leagues with its massive investment at $12/share. CRON stock went on to hit $25. Altria got a lot less attention with its recent investment in Lexaria, but it may end up having a similar effect. Earlier this year, Altria agreed to invest up to $12 million into Lexaria.Why did it do that? Lexaria has a novel patented technique for oral delivery of drugs. Obviously, this potentially has a huge market in the medicinal marijuana space. As it is, Altria has validated the technology by investing in it and seeking to commercialize it for nicotine. At $1.30 a share and a $100 million market cap, LXRP stock is still highly speculative. But unlike many medical cannabis stocks, Lexaria has promising technology and enough financial backing to potentially deliver strong results for its investors.At the time of this writing, Ian Bezek owned MO stock. You can reach him on Twitter at @irbezek. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The 7 Best Video Game Stocks to Power Up Your Portfolio! * 7 Forever Stocks to Buy for Long-Term Gains * 5 Self-Driving Car Stocks to Buy Compare Brokers The post Should You Buy, Sell, Or Hold These 7 Medical Cannabis Stocks? appeared first on InvestorPlace.
- ACCESSWIRE•8 days ago
Biotech Plays in the News You Should Know
HENDERSON, NV / ACCESSWIRE / February 12, 2019 / Below are several companies in the biotech space that are making news and drawing investor interest. These companies have the potential to make investors ...
- Motley Fool•9 days ago
Here's Why Cara Therapeutics Stock Rose 17.3% in January
An important phase 3 clinical trial enrolled its last patient at the beginning of the year, which means top-line results could be right around the corner.
- ACCESSWIRE•12 days ago
These 4 Marijuana Stocks Are Looking Strong
CORAL GABLES, FL / ACCESSWIRE / February 8, 2019 / The marijuana stock market has managed to flourish over the last few years, despite the fact that cannabis itself remains illegal under federal law as a Schedule I narcotic. It's almost laughable that marijuana is held to the same illegal regard as heroin or LSD, when modern science has made it quite clear that cannabis can actually benefit patients suffering from inflammatory diseases, anxiety, and countless other ailments. Nabis Holdings (INNPF) (NAB), Green Thumb Industries Inc (GTBIF), Cara Therapeutics Inc (CARA), and Curaleaf Holdings Inc (OTC PINK: CURLF) are four cannabis companies working to propel their industry into the future.
- ACCESSWIRE•14 days ago
Watch These Marijuana Stocks Hit The Ground Running On Wednesday (2/6/19)
American Premium Water Corporation (OTC:HIPH), iAnthus Capital Holdings Inc (ITHUF) (IAN.CN), PotNetwork Holdings Inc (OTC PINK: POTN), and Cara Therapeutics Inc (CARA) are 4 pot stocks that are bringing the heat on Wednesday. American Premium Water Corporation (OTC:HIPH) is a company you may not have heard of but could benefit from taking a look at. The Company is a luxury consumer products corporation invested in discovering different use cases for the molecular potential of hydrogen, as well as nanotechnologies, in congruence with cannabidiol (CBD) to optimize product offerings to treat health disorders and enhance the quality of life for consumers.
- Investopedia•15 days ago
Top Marijuana Stocks on the NASDAQ
Although the majority of U.S.-based cannabis companies and many foreign ADRs trade over-the-counter, a few marijuana companies are traded on the NASDAQ. Some investors prefer stocks that are listed on the NASDAQ to other exchanges due to their increased liquidity and tighter spreads than the OTC markets.
- ACCESSWIRE•15 days ago
Biotech Stocks to Watch
HENDERSON, NV / ACCESSWIRE / February 5, 2019 / In January, the trend in biotech stocks appeared to be on a positive sloping trajectory as the IBB capped off its strongest month in almost a year. Below ...
- Investopedia•18 days ago
New Cannabis Products Which Could Disrupt the Industry in 2019
The cannabis industry enjoyed tremendous investor enthusiasm in 2018, fueled in large part by major developments which seemed to open up the space for new opportunities. In spite of the fact that cannabis stocks overall failed to perform up to expectations last year, 2019 has already revealed continued anticipation regarding this growing industry. If cannabis stocks are to thrive going forward, it's likely that many companies will have some growing up to do.
- Motley Fool•19 days ago
Better Buy: GW Pharmaceuticals vs. Cara Therapeutics
Both of these biotech companies are getting close to achieving commercial successes.
- ACCESSWIRE•20 days ago
Biotechs Investors Are Flocking To
HENDERSON, NV / ACCESSWIRE / January 31, 2019 / Below are a few biotechnology stocks seeing a growing amount of investor interest which is the precursor for long term bull runs. One company who's on the ...
- Market Realist•21 days ago
Analyzing CARA, INSY, and GWPH’s Earnings Trends
CARA, INSY, and GWPH: Comparing Medical Cannabis Stocks(Continued from Prior Part)Earnings trends GW Pharmaceuticals’ (GWPH) net income was -$295.2 million in fiscal 2018—compared to -$170.5 million in fiscal 2017. In the first nine months of
Market Realist•21 days agoCannabis Stocks: CARA, INSY, and GWPH’s Revenue Trajectory
CARA, INSY, and GWPH: Comparing Medical Cannabis Stocks(Continued from Prior Part)Revenue trendsOn November 27, GW Pharmaceuticals (GWPH) presented its fourth-quarter and fiscal 2018 financial results. GW Pharmaceuticals’ net revenues in fiscal
- Market Realist•21 days ago
CARA, INSY, and GWPH: Analysts’ Recommendations in January
CARA, INSY, and GWPH: Comparing Medical Cannabis StocksStock performanceOn January 28, Cara Therapeutics’ (CARA) stock price closed at $14.82, which is an ~4.02% discount compared to its previous close and ~14% YTD (year-to-date) growth. The
- ACCESSWIRE•22 days ago
Cannabis and Biotech Stocks that Could Explode
HENDERSON, NV / ACCESSWIRE / January 29, 2019 / Small cap securities in the biotechnology industry are always of interest to investors because several events can help increase the stock's share price at ...
- ACCESSWIRE•23 days ago
Biotech Stocks to Watch this Week
HENDERSON, NV / ACCESSWIRE / January 28, 2019 / Biotech can be a lucrative sector for investors. Companies in the industry are often working toward well-defined goals such as clinical trial results, which ...
- Motley Fool•27 days ago
Is Cara Therapeutics a Buy?
The $600 million pharma company is working on a drug with estimated peak annual sales of $500 million.
- GlobeNewswire•27 days ago
Consolidated Research: 2019 Summary Expectations for First Data, IDEXX Laboratories, CMS Energy, Worthington Industries, Triumph Group, and Cara Therapeutics — Fundamental Analysis, Key Performance Indications
NEW YORK, Jan. 24, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Market Realist•28 days agoCara Therapeutics: Earnings Trends and Recent Developments
Cara Therapeutics Has Risen ~18% in January(Continued from Prior Part)Earnings trendsIn the first nine months of 2018, Cara Therapeutics (CARA) reported a net income and EPS of -$53.4 million and -$1.54, respectively—compared to -$43.9 million and
Market Realist•28 days agoCara Therapeutics: A Financial Overview in January
Cara Therapeutics Has Risen ~18% in January(Continued from Prior Part)Revenue trendsIn the first nine months of 2018, Cara Therapeutics (CARA) generated revenues of $7.9 million—compared to $911,000 during the same period the previous year. In
- Market Realist•28 days ago
Cara Therapeutics Has Risen ~18% in January
Cara Therapeutics Has Risen ~18% in JanuaryStock performance Cara Therapeutics’ (CARA) stock price reached $15.35 on January 18—compared to $13.00 when the market closed on December 31, which represents ~18% growth YTD (year-to-date). On January
- InvestorPlace•last month
With Trial Results Due, This Could Be a Breakout Year for Cara Stock
Cara Therapeutics (NASDAQ: CARA) continues its study on KORSUVA (difelikefalin), used for dialysis-dependent CKD patients with pruritus. Even though the primary completion date is in March, Cara stock will probably not move until afterward, if at all. Still, an improving score on the itching intensity scale could only help the stock. But first, all eyes will be on Cara's quarterly earnings report. * 7 Retail Stocks to Buy for the Rise of Menswear ### Last Quarter's Earnings Report Recap Cara reported third-quarter results in Nov. 2018. Earnings were not in the spotlight because the company lost $19.4 million, or $0.51 per basic share. It brought in $5 million in revenue, stemming from license and milestone fees. InvestorPlace - Stock Market News, Stock Advice & Trading Tips In the quarter, Cara solidified its balance sheet in a way that is typical with emerging biotech firms: it sold shares. The public offering netted $92.1 million, with 5.175 million shares issued at $19 a share. Though the stock traded as low as around $12 during Dec. 2018's sell-off, it recovered back to $15.43. This is still well off from the share issuance price. ### Phase Three Progress The phase three study of Korsuva (CR845) across its pipeline for pruritus is the highlight of its Q3 activity. This involved enrolling subjects across 60 U.S. sites. By the end of 2018, Cara should have had 80 U.S. sites and 350 patients enrolled in both the KALM-1 and KALM-2 studies. Both trials are designed to investigate the dose efficacy of Korsuva at 0.5 micrograms per kilo compared to a placebo. This is administered three times a week, for 12 weeks. Given that shares are somewhat range-bound, markets are in wait-and-see mode with the primary efficacy endpoint results. The secondary endpoint will measure the quality of life, including itch levels. Cara Pharmaceuticals expects the trial completed within the first half of 2019. ### Cash Burn Rate and Cara Stock Knowing how much cash a biotech company is burning is useful. It may give shareholders an idea on when Cara may sell shares again and potentially pressuring its share price. In its third quarter, R&D costs rose to $22.3 million, up from $9.2 million in the same period of 2017. Clinical trial costs rose last year, as did stock compensation and staffing costs. Cara ended with $206.1 million in cash at the end of Sep 30, 2018. Without accounting for any potential milestone payments, Cara has enough cash to carry on its research work through into 2021. ### Product Commercialization Cara's products are too early in the study phase to be thinking and planning a product commercialization plan. So, the near-term catalysts for CARA stock will be the clinical results from its studies. Fortunately, management believes it faces minimal competition for CKD-related pruritus. Its drug shows effectiveness, compared to the alternative treatment options. ### Outlook for CARA Stock in 2019 Last year was loaded with clinical trial activities for Cara. The stock traded at between $11.43 and $24.30. Much of the drop is attributable to the drop in the biotech sector. This selling accelerated in Dec. 2018. Results from the studies involving pruritus are positive catalysts for the stock for 2019. If the drug is approved, Cara receives $30 million for the regulatory approval step. Commercial milestones will bring in up to $440 million. So at the $600 market cap, investors are paying only a dollar in market value for the milestone revenue received from its partner, VFMCRP. ### Risks Investing in Cara is not without risks. Any disappointing results from the studies could send CARA stock sharply lower. A general sell-off in the markets will hurt biotech stocks even more. In bearish times, markets tend to punish speculative companies that do not have a product on the market or a study stream of revenue to count on. Disclaimer: None ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Companies Apple Should Consider Buying * 7 Beaten-Up Housing Stocks Due for a Bounce Back * Take Buffett's Advice: 5 Vanguard Funds to Buy Compare Brokers The post With Trial Results Due, This Could Be a Breakout Year for Cara Stock appeared first on InvestorPlace.
- Market Realist•last month
These Cannabis Stocks Are Soaring in January
These Cannabis Stocks Are Soaring in JanuaryCannabis stock trendsCannabis stock CannTrust Holdings (CNTTF) rose to $6.0 on January 15 from $4.8 at the close of market on December 31, 2018, representing a rise of ~25% in the first half of January
- Benzinga•last month
Bank Of America Takes Neutral Stance On Cara Therapeutics Ahead Of Phase 3 Korsuva Results
Cara Therapeutics Inc (NASDAQ: CARA ) got some love from Wall Street on Tuesday, with one analyst projecting significant upside for the stock based the outlook for its leading drug candidate. The Analyst ...
- Market Realist•last month
How Is INSYS Therapeutics Financially Positioned in January?
Cannabis Stock INSYS Therapeutics Is on the Rise in January (Continued from Prior Part) ## Revenue trends In the first nine months of 2018, INSYS Therapeutics’ net revenues declined ~40% YoY to reach $109.2 million from $65.7 million. In the third quarter, the company’s revenues declined ~40% YoY to reach $18.3 million from $30.7 million. Wall Street analysts estimate that INSYS Therapeutics is expected to generate revenues of $17.95 million in the fourth quarter of fiscal 2018, which represents a ~42.99% YoY decline. Analysts also estimate that INSYS Therapeutics will report net revenues of $83.74 million for fiscal 2018, which represents a ~40.48% YoY decline. Analysts estimate that GW Pharmaceuticals (GWPH) and Cara Therapeutics (CARA), INSYS Therapeutics’ peers in the cannabinoid drugs market, will report net revenues of $8.7 million and $10.9 million, respectively. GW Pharmaceuticals is expected to deliver ~13.52% YoY revenue growth in fiscal 2018. INSYS Therapeutics and Lunatus signed a licensing agreement for the commercialization of Subsys in the Middle East market. The agreement could boost INSYS Therapeutics’ global footprint and business growth. ## Expenditure trends In the first nine months of 2018, INSYS Therapeutics’ cost of revenue amounted to $8.2 million compared to $16.0 million in the same period the prior year. Wall Street analysts anticipate INSYS Therapeutics’ cost of revenue to be around $9.7 million in fiscal 2018. In the first nine months of 2018, INSYS Therapeutics’ net expenses in sales and marketing (or S&M) amounted to $25.5 million compared to $41.7 million in the same period the prior year. INSYS Therapeutics reported R&D (research & development) and G&A (general & administrative) expenses of $43.2 million and $29.3 million, respectively, compared to $46.6 million and $31.8 million in the same period the prior year. Wall Street analysts estimate that the company’s S&M, G&A, and R&D expenditure will be around $32.49 million, $89.50 million, and $58.78 million, respectively, in fiscal 2018. Continue to Next Part Browse this series on Market Realist: * Part 1 - Cannabis Stock INSYS Therapeutics Has Risen 28% in January * Part 3 - How INSYS Therapeutics’ Earnings Were Trending
